OTCMKTS:CYDYCytoDyn Stock Price, Forecast & News

CytoDyn's stock was trading at $1.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CYDY stock has increased by 522.3% and is now trading at $6.41. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytoDyn in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for CytoDyn.

CytoDyn is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for CytoDyn.

CytoDyn Inc (OTCMKTS:CYDY) announced its earnings results on Thursday, April, 9th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.02. View CytoDyn's earnings history.

1 Wall Street analysts have issued twelve-month price objectives for CytoDyn's shares. Their forecasts range from $4.00 to $4.00. On average, they expect CytoDyn's share price to reach $4.00 in the next twelve months. This suggests that the stock has a possible downside of 37.6%. View analysts' price targets for CytoDyn.

Headlines about CYDY stock have trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CytoDyn earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about CytoDyn.

Some companies that are related to CytoDyn include GALAPAGOS NV/S (GLPG), Sarepta Therapeutics (SRPT), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Ascendis Pharma A/S (ASND) and Bausch Health Companies (BHC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Rexahn Pharmaceuticals (REXN), Senseonics (SENS), Micron Technology (MU), United Therapeutics (UTHR) and Opko Health (OPK).

CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."

Shares of CYDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYDY stock can currently be purchased for approximately $6.41.

CytoDyn has a market capitalization of $3.45 billion. The biotechnology company earns $-56,190,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. CytoDyn employs 6 workers across the globe.

The official website for CytoDyn is www.cytodyn.com.

CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company can be reached via phone at 360-980-8524 or via email at [email protected]